MYC and cancer: The discovery of BETis has resulted in an increased focus on targeting chromatin modification “readers.” Recent studies have shown that two BETis are effective in the downregulation of the MYC oncogene in several cancer subtypes, suggesting the importance of these inhibitors in oncogenic regulation and for cancer therapies (Filippakopoulos et al., 2010; Dawson Mark and Kouzarides, 2012).